July 23, 2013
1 min read

Once-daily prostaglandin analog reduces IOP up to 24 hours

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

IOP was reduced up to 24 hours in patients with open-angle glaucoma or hypertension when treated with a once-daily travoprost ophthalmic solution, according to a study.

“The sustained 30% reduction in IOP seen with travoprost therapy may be a reasonable target for patients with open-angle glaucoma or hypertension,” Harvey DuBiner, MD, and colleagues reported in a poster presented at the World Glaucoma Congress. An IOP reduction threshold for glaucoma patients has yet to be determined.

Seven clinical trials were examined, including a total of 1,563 patients treated with travoprost ophthalmic solution 0.004% monotherapy daily for 12 weeks. IOP was measured at three times during the day (8 a.m. or 9 a.m., 10 a.m. or 11 a.m., and 4 p.m.) at baseline, 2 weeks and 12 weeks. 

Average reduction of IOP was7.96mm Hg at week 2 and 8mm Hg at week 12. There was a 30% decrease in IOP for up to 24 hours after treatment.

Travoprost’s IOP-lowering effects peaked as early as 2 weeks after dosing and were maintained throughout the 12 weeks of treatment, the authors said.

Disclosure: DuBiner is on the speaker’s bureau for Alcon.